Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting
November 05, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based...
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
September 17, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute...
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
August 09, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
August 05, 2019 08:05 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for...
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
May 28, 2019 09:05 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering...
Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
May 23, 2019 17:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price...
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
May 10, 2019 08:05 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
May 10, 2019 08:00 ET
|
Galectin Therapeutics Inc.
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 ...
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
April 15, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key...
Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
April 02, 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...